Head & VP, Business Development | Fortress Biotech
Building & maturing biotech newcos.
Oncology · Immunology · Rheumatology · Dermatology · Metabolic & GI Disorders · Rare & Orphan Diseases · Ophthalmology
Strategy consulting leader at Booz Allen and Deloitte Life Sciences, advising institutions, startups and established companies on:
Roundtable on how investment, partnerships and commercialization move scientific discovery to therapeutic breakthroughs. Moderated by Vineet Gupta, PhD (UTMB), with panelists Mohsin Khan (Fortress Biotech), Michael Torres (CrossBridge Bio) and Sahir Ali (Modi Ventures).
How novel and emerging oncology modalities stand out in a crowded market, from immunotherapies, mono- to multi-specific biologics, and cell and gene therapies to radiopharmaceuticals and novel drug combinations. The panel covered what investors and strategic partners look for: differentiation, translational milestones, clinical signals, and what drives real investment and partnering interest.
Moderated the summit’s panel on moving brain therapeutics from single programs to industrial-scale pipelines, with Murali Gopalakrishnan (VP & Head of Global Search & Eval, Teva Pharmaceuticals), Bill McKeon (CEO, Texas Medical Center), Luisa Salter-Cid (Osage University Partners) and Giulio Taglialatela (UTMB). A key point: it takes a village, deep science, durable commitment and better biomarkers to measure treatment response. Hosted by Center for Houston’s Future, Project Metis and UTMB.
Panel on how capital constraints and shifting valuations are driving strategic partnerships, investments, licensing and M&A, covering capital markets, therapeutic priorities and regulatory inflection points. Moderated by Brian Bewley and Sung Park (Partners at Reed Smith LLP) with speakers including Mohsin Khan (Head & VP - BD, Fortress Biotech), Eason Hahm (Director Investment Banking, William Blair), Allison Molkenthin (Managing Director, Bently Associates), Cori Goldberg (Partner, Reed Smith LLP) and Jason Kim (Director, BD&L, Merck).
Proposed “connected access”: treating access to care like a dosed therapy, matching the provider, channel, frequency and timing to each patient’s needs through wearables, apps and telehealth. The model anticipated today’s AI-assisted, data-connected care.
About 30 research and thought leadership articles including: early cardiac progenitor cell research with Dr. Sunjay Kaushal identifying the cell secretome as the functional therapeutic unit (Circulation Research, 2017), which is the science behind Secretome Therapeutics; multiple thought leadership with Dr. Ronald Germain (noted immunologist and member of the National Academy of Medicine); and drug development policies, including leading the AAPS Stability Focus Group workshop with industry and FDA stakeholders (April 3–4, 2017, Rockville, MD) and writing guidelines on drug stability challenges that are not addressed by harmonized guidance (AAPS Open, 2018).
© 2026 Mohsin Khan